SCHEMBL6419807

SCHEMBL6419807

NN=C(c1ccc(O)cc1O)c1nc2nonc2nc1Nc1cccc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
POLB P06746 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
PIM1 P11309 2/20 0.37
PIM2 Q9P1W9 1/20 0.37
EGFR P00533 7/20 0.36
CDK2 P24941 2/20 0.36
PLK4 O00444 1/20 0.36
DAPK3 O43293 1/20 0.36
DYRK3 O43781 1/20 0.36
ROCK2 O75116 1/20 0.36
PRKD3 O94806 1/20 0.36
MAP4K4 O95819 1/20 0.36
RET P07949 1/20 0.36
FER P16591 1/20 0.36
PRKACA P17612 1/20 0.36
RPS6KB1 P23443 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6419800 1.00 TP53 (0.40) TP53MAPTSMN1; SMN2POLBESR1
SCHEMBL6415756 0.90 TP53 (0.41) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6415753 0.90 TP53 (0.41) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6436126 0.90 FADS1 (0.43) TP53MAPTSMN1; SMN2POLBEGFR
SCHEMBL6414923 0.89 CYP3A4 (0.38) TP53MAPTSMN1; SMN2POLBESR1
SCHEMBL6414910 0.89 CYP3A4 (0.38) TP53MAPTSMN1; SMN2POLBESR1
SCHEMBL6418345 0.88 TP53 (0.43) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6418364 0.88 TP53 (0.43) TP53MAPTSMN1; SMN2POLBPIM1
SCHEMBL6416484 0.87 MAPT (0.36) TP53MAPTSMN1; SMN2POLBESR1
SCHEMBL6416496 0.87 MAPT (0.36) TP53MAPTSMN1; SMN2POLBESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 TP53 4485/4885MAPT 4420/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.